Compare SWBI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | LXRX |
|---|---|---|
| Founded | 1852 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 651.8M | 703.3M |
| IPO Year | 2000 | 2000 |
| Metric | SWBI | LXRX |
|---|---|---|
| Price | $14.66 | $2.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $14.00 | $4.15 |
| AVG Volume (30 Days) | 588.1K | ★ 4.5M |
| Earning Date | 06-17-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | 36.67 | ★ 77.78 |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $523,845,000.00 | $49,803,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $3.72 | N/A |
| P/E Ratio | $35.20 | ★ N/A |
| Revenue Growth | 10.36 | ★ 60.24 |
| 52 Week Low | $7.73 | $1.00 |
| 52 Week High | $17.56 | $2.68 |
| Indicator | SWBI | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.78 | 52.23 |
| Support Level | $13.83 | $2.04 |
| Resistance Level | $15.24 | $2.53 |
| Average True Range (ATR) | 0.43 | 0.14 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 13.88 | 56.98 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.